BIOY vs XLVI

BIOYFGraniteShares YieldBOOST Biotech ETF

XLVIAState Street Health Care Select Sector SPDR Premium Income ETF

In short

BIOY Most sector income funds sell calls on the sector itself. BIOY goes one level up: it sells puts on a 3x leveraged biotech ETF, mining the fat premiums that come with one of the market's twitchiest wrappers, and pays cash out weekly.

XLVI Covered calls, pointed at one sector. XLVI owns State Street's health care sector ETF outright, then sells call options on that single fund, turning pharma, device and biotech exposure into a monthly income stream.

Stated mandate

BIOY The Fund seeks to generate three times the income from selling options on the S&P Biotechnology Select Industry Index through options on leveraged ETFs, while also seeking exposure to the leveraged ETF’s performance subject to a cap.

XLVI State Street describes an actively managed strategy seeking current income while preserving prospects for long-term capital growth. It invests in the State Street Health Care Select Sector SPDR ETF and sells call options on that ETF to generate additional income.

Why people hold it

• BIOY The income engine is the whole point: writing puts on a 3x biotech ETF harvests the elevated implied volatility leveraged funds throw off, with distributions paid weekly.graniteshares.com
• It doesn't hold the leveraged biotech ETF. Exposure runs through the options book, aiming at 3x the income from selling options on the S&P Biotechnology Select Industry Index.graniteshares.com
• One ticker replaces a standing options program: strike selection, short-dated expiries and the weekly roll are handled inside a 1940 Act fund.graniteshares.com
• GraniteShares discloses that payouts can include return of capital, so the character of each distribution is documented rather than left to guesswork.graniteshares.com

• XLVI One holding, one overlay: it owns the health care sector ETF and writes calls on that same fund rather than on dozens of individual names, so the income engine is easy to follow.ssga.com
• Income lands monthly, and State Street discloses up front that distributions can include return of capital, so you know what can be inside the check.
• The 0.35% fee sits right at the median for sector covered-call funds, and it buys an actively managed options sleeve instead of a fixed formula.
• Part of a same-priced sector suite (utilities XLUI, energy XLEI), so you can pick the sector and keep the mechanics identical. This one ranks among the strongest builds in that group.

Worth knowing

• BIOY At 1.07%, the fee runs about triple the 0.35% median of its sector-overlay peer group, where the State Street Premium Income funds (XLVI, XLUI) sit.
• The payoff shape is lopsided: upside is capped by design while the put book absorbs the downside of a 3x daily biotech ETF, a tool built for one-day moves.
• Small and thinly traded, and it only started trading in 2026, so there is little history behind it and execution costs deserve attention.

• XLVI Selling calls means selling upside. The premium is paid for by giving up part of the gain when health care runs hard, which is the core trade in this design.ssga.com
• Launched in 2025, so the track record is short and the fund is still building scale. Worth eyeing the bid-ask spread before trading.
• Single-sector concentration: everything rides on S&P 500 health care names, from drug pricing policy to FDA outcomes and patent cliffs.ssga.com

Full BIOY profile⁠

Full XLVI profile⁠